Candel Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Candel Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2023.
  • Candel Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$22.2M, a 131% decline year-over-year.
  • Candel Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$50M, a 55.3% decline year-over-year.
  • Candel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$37.9M, a 102% decline from 2022.
  • Candel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$18.8M, a 48% increase from 2021.
  • Candel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$36.1M, a 104% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$37.9M -$19.1M -102% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 -$18.8M +$17.3M +48% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 -$36.1M -$18.4M -104% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 -$17.7M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.